Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 in and Promotes Tumorigenesis in Mice.

Dandawate P, Ghosh C, Palaniyandi K, Paul S, Rawal S, Pradhan R, Ali Sayed AA, Choudhury S, Standing D, Subramaniam D, Padhye S, Gunewardena S, Thomas SM, Neil MO, Tawfik O, Welch DR, Jensen RA, Maliski S, Weir S, Iwakuma T, Anant S, Dhar A.

Gastroenterology. 2019 Aug 20. pii: S0016-5085(19)41232-8. doi: 10.1053/j.gastro.2019.08.018. [Epub ahead of print]

PMID:
31442435
2.

TP53 in bone and soft tissue sarcomas.

Thoenen E, Curl A, Iwakuma T.

Pharmacol Ther. 2019 Oct;202:149-164. doi: 10.1016/j.pharmthera.2019.06.010. Epub 2019 Jul 2. Review.

PMID:
31276706
3.

Ubiquinol-cytochrome C reductase core protein II promotes tumorigenesis by facilitating p53 degradation.

Han Y, Wu P, Wang Z, Zhang Z, Sun S, Liu J, Gong S, Gao P, Iwakuma T, Molina-Vila MA, Chen BP, Zhang Y, Ji T, Mo Q, Chen P, Hu J, Wang S, Zhou J, Lu H, Gao Q.

EBioMedicine. 2019 Feb;40:92-105. doi: 10.1016/j.ebiom.2019.01.002. Epub 2019 Jan 20.

4.

Regulators of Oncogenic Mutant TP53 Gain of Function.

Yamamoto S, Iwakuma T.

Cancers (Basel). 2018 Dec 20;11(1). pii: E4. doi: 10.3390/cancers11010004. Review.

5.

MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma.

Ranjan A, Iyer SV, Ward C, Link T, Diaz FJ, Dhar A, Tawfik OW, Weinman SA, Azuma Y, Izumi T, Iwakuma T.

Oncotarget. 2018 Apr 20;9(30):21429-21443. doi: 10.18632/oncotarget.25117. eCollection 2018 Apr 20.

6.

Emerging Non-Canonical Functions and Regulation of p53.

Ranjan A, Iwakuma T.

Int J Mol Sci. 2018 Mar 28;19(4). pii: E1015. doi: 10.3390/ijms19041015.

7.

Comparative oncology approach to drug repurposing in osteosarcoma.

Parrales A, McDonald P, Ottomeyer M, Roy A, Shoenen FJ, Broward M, Bruns T, Thamm DH, Weir SJ, Neville KA, Iwakuma T, Fulbright JM.

PLoS One. 2018 Mar 26;13(3):e0194224. doi: 10.1371/journal.pone.0194224. eCollection 2018.

8.

The interplay between mutant p53 and the mevalonate pathway.

Parrales A, Thoenen E, Iwakuma T.

Cell Death Differ. 2018 Mar;25(3):460-470. doi: 10.1038/s41418-017-0026-y. Epub 2017 Dec 13. Review.

9.

Regulation of cytotoxic T-cell responses by p53 in cancer.

Braun MW, Iwakuma T.

Transl Cancer Res. 2016 Dec;5(6):692-697. doi: 10.21037/tcr.2016.11.76.

10.

Nischarin inhibition alters energy metabolism by activating AMP-activated protein kinase.

Dong S, Baranwal S, Garcia A, Serrano-Gomez SJ, Eastlack S, Iwakuma T, Mercante D, Mauvais-Jarvis F, Alahari SK.

J Biol Chem. 2017 Oct 13;292(41):16833-16846. doi: 10.1074/jbc.M117.784256. Epub 2017 Aug 24.

11.

Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma.

Kundu AK, Iyer SV, Chandra S, Adhikari AS, Iwakuma T, Mandal TK.

PLoS One. 2017 Jun 21;12(6):e0179168. doi: 10.1371/journal.pone.0179168. eCollection 2017.

12.

Unsaturated fatty acids regulate stemness of ovarian cancer cells through NF-κB.

Parrales A, Ranjan A, Iwakuma T.

Stem Cell Investig. 2017 Jun 3;4:49. doi: 10.21037/sci.2017.05.07. eCollection 2017. No abstract available.

13.

RIPK1-TRAF2 interplay on the TNF/NF-κB signaling, cell death, and cancer development in the liver.

Yamamoto S, Iwakuma T.

Transl Cancer Res. 2017 May;6(Suppl 3):94-109. doi: 10.21037/tcr.2017.04.01. No abstract available.

14.

Suppressive roles of A3AR and TMIGD3 i1 in osteosarcoma malignancy.

Ranjan A, Iyer SV, Iwakuma T.

Cell Cycle. 2017 May 19;16(10):903-904. doi: 10.1080/15384101.2017.1308153. Epub 2017 Mar 29. No abstract available.

15.

Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer.

Sasaki K, Kurahara H, Young ED, Natsugoe S, Ijichi A, Iwakuma T, Welch DR.

Clin Exp Metastasis. 2017 Apr;34(3-4):229-239. doi: 10.1007/s10585-017-9840-3. Epub 2017 Mar 13.

16.

Roles of p53 in extrinsic factor-induced liver carcinogenesis.

Link T, Iwakuma T.

Hepatoma Res. 2017;3:95-104. doi: 10.20517/2394-5079.2017.07. Epub 2017 Jun 6.

17.

p53 as a Regulator of Lipid Metabolism in Cancer.

Parrales A, Iwakuma T.

Int J Mol Sci. 2016 Dec 10;17(12). pii: E2074. Review.

18.

Non-Canonical Cell Death Induced by p53.

Ranjan A, Iwakuma T.

Int J Mol Sci. 2016 Dec 9;17(12). pii: E2068. Review.

19.

Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-κB and osteosarcoma progression.

Iyer SV, Ranjan A, Elias HK, Parrales A, Sasaki H, Roy BC, Umar S, Tawfik OW, Iwakuma T.

Nat Commun. 2016 Nov 25;7:13561. doi: 10.1038/ncomms13561.

20.

DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.

Parrales A, Ranjan A, Iyer SV, Padhye S, Weir SJ, Roy A, Iwakuma T.

Nat Cell Biol. 2016 Nov;18(11):1233-1243. doi: 10.1038/ncb3427. Epub 2016 Oct 24.

21.

Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen.

Kurahara H, Bohl C, Natsugoe S, Nishizono Y, Harihar S, Sharma R, Iwakuma T, Welch DR.

Int J Cancer. 2016 Aug 1;139(3):628-38. doi: 10.1002/ijc.30110.

22.

Targeting Oncogenic Mutant p53 for Cancer Therapy.

Parrales A, Iwakuma T.

Front Oncol. 2015 Dec 21;5:288. doi: 10.3389/fonc.2015.00288. eCollection 2015. Review.

23.

Murine double minute 2, a potential p53-independent regulator of liver cancer metastasis.

Ranjan A, Bera K, Iwakuma T.

Hepatoma Res. 2016;2:114-121. doi: 10.20517/2394-5079.2015.67. Epub 2016 May 6.

24.

Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.

Iyer SV, Parrales A, Begani P, Narkar A, Adhikari AS, Martinez LA, Iwakuma T.

Oncotarget. 2016 Feb 2;7(5):5401-15. doi: 10.18632/oncotarget.6634.

25.

An improved intrafemoral injection with minimized leakage as an orthotopic mouse model of osteosarcoma.

Sasaki H, Iyer SV, Sasaki K, Tawfik OW, Iwakuma T.

Anal Biochem. 2015 Oct 1;486:70-4. doi: 10.1016/j.ab.2015.06.030. Epub 2015 Jun 30.

26.

MTBP inhibits migration and metastasis of hepatocellular carcinoma.

Bi Q, Ranjan A, Fan R, Agarwal N, Welch DR, Weinman SA, Ding J, Iwakuma T.

Clin Exp Metastasis. 2015 Apr;32(4):301-11. doi: 10.1007/s10585-015-9706-5. Epub 2015 Mar 11.

27.

Furin is the major proprotein convertase required for KISS1-to-Kisspeptin processing.

Harihar S, Pounds KM, Iwakuma T, Seidah NG, Welch DR.

PLoS One. 2014 Jan 13;9(1):e84958. doi: 10.1371/journal.pone.0084958. eCollection 2014.

28.

Metastasis suppressor KISS1 seems to reverse the Warburg effect by enhancing mitochondrial biogenesis.

Liu W, Beck BH, Vaidya KS, Nash KT, Feeley KP, Ballinger SW, Pounds KM, Denning WL, Diers AR, Landar A, Dhar A, Iwakuma T, Welch DR.

Cancer Res. 2014 Feb 1;74(3):954-63. doi: 10.1158/0008-5472.CAN-13-1183. Epub 2013 Dec 18.

29.

A novel link between the HER2-Akt and MDM2-p53 pathways via CSN6.

Iyer SV, Iwakuma T.

Cell Cycle. 2012 Nov 15;11(22):4112. doi: 10.4161/cc.22606. Epub 2012 Oct 25. No abstract available.

30.

MDM2 binding protein, a novel metastasis suppressor.

Iwakuma T, Agarwal N.

Cancer Metastasis Rev. 2012 Dec;31(3-4):633-40. doi: 10.1007/s10555-012-9364-x. Review.

PMID:
22684342
31.

MTBP suppresses cell migration and filopodia formation by inhibiting ACTN4.

Agarwal N, Adhikari AS, Iyer SV, Hekmatdoost K, Welch DR, Iwakuma T.

Oncogene. 2013 Jan 24;32(4):462-70. doi: 10.1038/onc.2012.69. Epub 2012 Feb 27.

32.

IL-7Rα deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis.

Kibe R, Zhang S, Guo D, Marrero L, Tsien F, Rodriguez P, Khan S, Zieske A, Huang J, Li W, Durum SK, Iwakuma T, Cui Y.

Cell Death Differ. 2012 Jul;19(7):1139-51. doi: 10.1038/cdd.2011.203. Epub 2012 Jan 27.

33.

Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability.

Pant V, Xiong S, Iwakuma T, Quintás-Cardama A, Lozano G.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):11995-2000. doi: 10.1073/pnas.1102241108. Epub 2011 Jul 5.

34.

Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis.

Zhang S, Zheng M, Kibe R, Huang Y, Marrero L, Warren S, Zieske AW, Iwakuma T, Kolls JK, Cui Y.

FASEB J. 2011 Jul;25(7):2387-98. doi: 10.1096/fj.10-175299. Epub 2011 Apr 6.

35.

Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers.

Zhao R, Yeung SC, Chen J, Iwakuma T, Su CH, Chen B, Qu C, Zhang F, Chen YT, Lin YL, Lee DF, Jin F, Zhu R, Shaikenov T, Sarbassov D, Sahin A, Wang H, Wang H, Lai CC, Tsai FJ, Lozano G, Lee MH.

J Clin Invest. 2011 Mar;121(3):851-65. doi: 10.1172/JCI44111. Epub 2011 Feb 7.

36.

MTBP plays a crucial role in mitotic progression and chromosome segregation.

Agarwal N, Tochigi Y, Adhikari AS, Cui S, Cui Y, Iwakuma T.

Cell Death Differ. 2011 Jul;18(7):1208-19. doi: 10.1038/cdd.2010.189. Epub 2011 Jan 28.

37.

Metastatic potential of tumor-initiating cells in solid tumors.

Adhikari AS, Agarwal N, Iwakuma T.

Front Biosci (Landmark Ed). 2011 Jan 1;16:1927-38. Review.

PMID:
21196274
38.

A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.

Post SM, Quintás-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, Maccio DR, Bond GL, Johnson DG, Levine AJ, Lozano G.

Cancer Cell. 2010 Sep 14;18(3):220-30. doi: 10.1016/j.ccr.2010.07.010.

39.

CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance.

Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR, Iwakuma T.

Cancer Res. 2010 Jun 1;70(11):4602-12. doi: 10.1158/0008-5472.CAN-09-3463. Epub 2010 May 11.

40.

A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis.

Odvody J, Vincent T, Arrate MP, Grieb B, Wang S, Garriga J, Lozano G, Iwakuma T, Haines DS, Eischen CM.

Oncogene. 2010 Jun 3;29(22):3287-96. doi: 10.1038/onc.2010.82. Epub 2010 Mar 22.

41.

Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.

Adhikari AS, Iwakuma T.

Fukuoka Igaku Zasshi. 2009 Jun;100(6):217-28. Review.

PMID:
19670804
42.

Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-MDM2 signaling pathway.

Busso CS, Iwakuma T, Izumi T.

Oncogene. 2009 Apr 2;28(13):1616-25. doi: 10.1038/onc.2009.5. Epub 2009 Feb 16.

43.

Comparison of general water quality of rivers in Indonesia and Japan.

Kido M, Yustiawati, Syawal MS, Sulastri, Hosokawa T, Tanaka S, Saito T, Iwakuma T, Kurasaki M.

Environ Monit Assess. 2009 Sep;156(1-4):317-29. doi: 10.1007/s10661-008-0487-z. Epub 2008 Aug 30.

44.

Mdm2 and Mdm4 loss regulates distinct p53 activities.

Barboza JA, Iwakuma T, Terzian T, El-Naggar AK, Lozano G.

Mol Cancer Res. 2008 Jun;6(6):947-54. doi: 10.1158/1541-7786.MCR-07-2079.

45.

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.

Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G.

Genes Dev. 2008 May 15;22(10):1337-44. doi: 10.1101/gad.1662908.

47.

Mtbp haploinsufficiency in mice increases tumor metastasis.

Iwakuma T, Tochigi Y, Van Pelt CS, Caldwell LC, Terzian T, Parant JM, Chau GP, Koch JG, Eischen CM, Lozano G.

Oncogene. 2008 Mar 20;27(13):1813-20. Epub 2007 Oct 1.

PMID:
17906694
48.

Crippling p53 activities via knock-in mutations in mouse models.

Iwakuma T, Lozano G.

Oncogene. 2007 Apr 2;26(15):2177-84. Review.

PMID:
17401426
49.

Li-Fraumeni syndrome: a p53 family affair.

Iwakuma T, Lozano G, Flores ER.

Cell Cycle. 2005 Jul;4(7):865-7. Epub 2005 Jul 4. Review.

PMID:
15917654
50.

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G.

Cell. 2004 Dec 17;119(6):861-72.

Supplemental Content

Loading ...
Support Center